AzTrials
AzTrials

Amyotrophic Lateral SclerosisCFTSLANCT05768646

Counterfactual Thinking in Amyotrophic Lateral Sclerosis

An observational study of Amyotrophic Lateral Sclerosis, run by Istituto Auxologico Italiano at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The properness of our past choices and action is usually judged according to what could have been if we had behaved differently. This ability to simulate alternatives to past factual events and actions is called counterfactual thinking (CFT) and is closely related to the decision-making process and future behaviors. Read more about this study

Who is it for?
Ages 25 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Amyotrophic Lateral Sclerosis
What is being tested?
Neuropsychological instruments
How many people
157 participants
Where
1 siteItaly
Study dates
31 Mar 2021to 30 Sep 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: ALS patients coming to clinical attention and community resident healthy controls

Who may be able to join

  • Patients: probable or definite ALS
  • Healthy controls: not applicable

Who cannot join

  • Patients: other brain disorders; severe general medical conditions and uncorrected visual/hearing deficits
  • Healthy controls: brain disorders; severe general medical conditions and uncorrected visual/hearing deficits

Trial locations and contacts

1 site in 1 country.

Barbara Poletti, Ph.D. contact

+0261911 ext. 2609

b.poletti@auxologico.it

Italy1 site, 1 recruiting
  • Istituto Auxologico Italiano

    Milan, 20149

    Barbara Poletti, Ph.D, +390261911 ext. 2609, b.poletti@auxologico.it

    Recruiting

Other trials in Italy

About this study

Official title: Counterfactual Thinking Assessment in Amyotrophic Lateral Sclerosis

The properness of our past choices and action is usually judged according to what could have been if we had behaved differently. This ability to simulate alternatives to past factual events and actions is called counterfactual thinking (CFT) and is closely related to the decision-making process and future behaviors. In fact, the generation of CFT fulfills an important preparatory function, since it offers behavioral instructions that can guide the individual in facing similar decision-making problems in the future. Consequently, a damage or a reduction in the CFT are likely to impact on the individual's decision-making (DM) ability, especially regarding crucial decisions such as those in the medical field. In recent years, growing evidence has highlighted alterations in CFT in several neurological, neurodegenerative and psychiatric conditions, such as Huntington's disease, Parkinson's disease, prefrontal cortex damage, schizophrenia, obsessive-compulsive disorder and major depressive disorder, underlining how CFT deficits are specifically associated with frontal-executive dysfunction. These alterations, as mentioned, can lead to non-optimal DM processes and behaviors.

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of motor neurons in the spinal cord, brain stem and motor cortex. Literature data have highlighted the presence of cognitive and behavioral alterations as integral parts of the disease, as a part of a continuum, with a partial overlap, between ALS and frontotemporal dementia (FTD). The progressive and fatal course of the disease and the presence of cognitive/behavioral alterations, together with the impairment in communication skills, have significant implications on patient's competence in the advance care planning, especially regarding informed consent to advance treatment and end-of-life decision. In particular, patients' perspectives about therapeutic choices and end-of-life interventions are likely to be influenced by cognitive-behavioral aspects, where the integrity of frontal-executive functions plays a crucial role in patients' DM ability.

Read more

The investigators hypothesize that ALS patients will show a certain deficit in CFT, both in the ability to generate counterfactual thoughts related to a negative real-life and in the ability to use CFT to make causal inferences in fictional social scenarios. Moreover, a relationship between CFT and DM abilities is expected to be found. These expected impairments are likely to be associated with the cognitive and behavioral alterations that typically occur in ALS.

Primary aim The primary purpose of the study is to investigate the integrity of CFT ability in patients with ALS.

Specifically, this study aims to: (1) evaluate the functioning of the CFT in a group of patients affected by ALS; (2) investigate how the functioning of the CFT is associated with the ALS typical cognitive-behavioral alterations; (3) evaluate the possible association between CFT and DM abilities; (4) investigate how clinical, psychological, cognitive and behavioral variables affect CFT integrity.

Secondary aim CFT ability will be investigated along the course of the disease, with patients being recruited in a longitudinal study. When possible, according to clinical conditions, patients will be assessed at 0-6-12-24 months, in order to better characterize CFT and DM functioning over time, as well as patients' cognitive-behavioral profile. .

We expect to highlight a deficit or a reduction in patients' CFT ability and such alteration is likely to be associated with DM skills, as well as with the specific cognitive and behavioral profile of ALS patients.

Being tested
Neuropsychological instruments
Medical subject headings
Amyotrophic Lateral Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neuropsychological instrumentsBehavioural

    Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features

Study groups in NCT05768646
Study groupRoleWhat they receive
ALS patientsNot described
Receives: Behavioral: Neuropsychological instruments
Healthy controlsNot described
Receives: Behavioral: Neuropsychological instruments

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Counterfactual Inference Test

    Performance-based tests assessing the ability to use CFT in order to make inferences

    Measured: At enrollment

  2. Spontaneous Counterfactual Generation Test

    Performance-based tests assessing CFT abilities, in particular the frequency of CFT generated in response to a personal, real-life event.

    Measured: At enrollment

Secondary outcomes (1)
  1. Longitudinal assessment of CFT abilities

    Performance-based tests assessing the ability to use CFT in order to make inferences (i.e. Counterfactual Inference Test) and the frequency of CFT generated in response to a personal, real-life event (i.e., Spontaneous Counterfactual Generation Test) will be administered along the course of the disease, with patients being recruited in a longitudinal study. When possible, according to clinical conditions, patients will be assessed at 0-6-12-24 months, in order to better characterize CFT functioning over time.

    Measured: At enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Mar 2023
  2. Study start31 Mar 2021
  3. Primary completion30 Sep 2023 (estimated)
  4. Study completion30 Sep 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
157 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05768646
Sponsor's protocol ID
23C122
Acronym
CFTSLA
Status last verified
Mar 2023
First submitted
22 Feb 2023
Last updated
14 Mar 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Amyotrophic Lateral Sclerosis, run by Istituto Auxologico Italiano at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Barbara Poletti, Ph.D. (+0261911 ext. 2609, b.poletti@auxologico.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Counterfactual Inference Test (time frame: At enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
CFTSLA Clinical Trial NCT05768646 | AzTrials